Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2020 | Cytostatic Therapy | Original Article – Cancer Research

Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1

Authors: Yong Hoi Lee, Siew Wai Pang, Esther Revai Lechtich, Khalid Shah, Samson Eugin Simon, Suriyan Ponnusamy, Ramesh Narayanan, Chit Laa Poh, Kuan Onn Tan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2020

Abstract

Purpose

Although important for apoptosis, the signaling pathway involving MOAP-1(Modulator of Apoptosis 1), RASSF1A (RAS association domain family 1A), and Bax (Bcl-2 associated X protein) is likely to be dysfunctional in many types of human cancers due to mechanisms associated with gene mutation and DNA hyper-methylation. The purpose of the present study was to assess the potential impact of generating physiologically relevant signaling pathway mediated by MOAP-1, Bax, and RASSF1A (MBR) in cancer cells and chemo-drug resistant cancer cells.

Methods

The tricistronic expression construct that encodes MOAP-1, Bax, and RASSF1A (MBR) or its mutant, MOAP-1∆BH3L, Bax and RASSF1A (MBRX) was expressed from an IRES (Internal Ribosome Entry Site)-based tricistronic expression vector in human breast cancer cells, including MCF-7, MCF-7-CR (cisplatin resistant) and triple negative breast cancer cells, BMET05, for functional characterization through in vitro and in vivo models.

Results

Transient expression of MBR potently promoted dose-dependent apoptotic signaling and chemo-sensitization in the cancer cells, as evidenced by loss of cell viability, nuclei condensation and Annexin-V positive staining while stable expression of MBR in MCF-7 cells significantly reduced the number of MBR stable clone by 86% and the stable clone exhibited robust chemo-drug sensitivity. In contrast, MBRX stable clone exhibited chemo-drug resistance while transiently over-expressed MOAP-1ΔBH3L inhibited the apoptotic activity of MBR. Moreover, the spheroids derived from the MBR stable clone displayed enhanced chemo-sensitivity and apoptotic activity. In mouse xenograft model, the tumors derived from MBR stable clone showed relatively high level of tumor growth retardation associated with the increase in apoptotic activity, leading to the decreases in both tumor weight and volume.

Conclusions

Expression of MBR in cancer cells induces apoptotic cell death with enhanced chemo-sensitization requiring the BH3L domain of MOAP-1. In animal model, the expression of MBR significantly reduces the growth of tumors, suggesting that MBR is a potent apoptotic sensitizer with potential therapeutic benefits for cancer treatment.

Acconcia F, Marino M (2011) The effects of 17β-estradiol in cancer are mediated by estrogen receptor signaling at the plasma membrane. Front Physiol JUN. https://doi.org/10.3389/fphys.2011.00030 CrossRef

Albert ML, Darnell RB (2004) Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4:36–44. https://doi.org/10.1038/nrc1255 CrossRefPubMed

Baksh S, Tommasi S, Fenton S et al (2005) The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to bax conformational change and cell death. Mol Cell 18:637–650. https://doi.org/10.1016/j.molcel.2005.05.010 CrossRefPubMed

Barnett M, Prosser J, Sutton I et al (2001) Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J Neurol Neurosurg Psychiatry 70:222–225. https://doi.org/10.1136/jnnp.70.2.222 CrossRefPubMedPubMedCentral

Chatelut E, Delord J-P, Canal P (2003) Toxicity patterns of cytotoxic drugs. Invest New Drugs 21:141–148. https://doi.org/10.1023/a:1023565227808 CrossRefPubMed

Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9:501–507. https://doi.org/10.1038/nrc2663 CrossRefPubMed

d’Amato TA, Landreneau RJ, Ricketts W et al (2007) Chemotherapy resistance and oncogene expression in non–small cell lung cancer. J Thorac Cardiovasc Surg 133:352–363. https://doi.org/10.1016/J.JTCVS.2006.10.019 CrossRefPubMed

Dall G, Vieusseux J, Unsworth A et al (2015) Low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J Cancer 6:1331–1336. https://doi.org/10.7150/jca.10890 CrossRefPubMedPubMedCentral

Dalmau J, Gultekin SH, Voltz R et al (1999) Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122:27–39. https://doi.org/10.1093/brain/122.1.27 CrossRefPubMed

Dammann R, Schagdarsurengin U, Seidel C et al (2005) The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 20:645–663. https://doi.org/10.14670/HH-20.645

Dammann R, Schagdarsurengin U, Strunnikova M, et al (2003) Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 18:665–677. https://doi.org/10.14670/HH-18.665

Dittfeld C, Richter AM, Steinmann K et al (2012) The SARAH Domain of RASSF1A and its tumor suppressor function. Mol Biol Int 2012:196715. https://doi.org/10.1155/2012/196715 CrossRefPubMedPubMedCentral

Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172. https://doi.org/10.1242/jcs.010389 CrossRefPubMed

Eun K, Ham SW, Kim H (2017) Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep 50:117–125. https://doi.org/10.5483/bmbrep.2017.50.3.222 CrossRefPubMedPubMedCentral

Foley CJ, Freedman H, Choo SL et al (2008) Dynamics of RASSF1A/MOAP-1 association with death receptors. Mol Cell Biol 28:4520–4535. https://doi.org/10.1128/MCB.02011-07 CrossRefPubMedPubMedCentral

Fu NY, Sukumaran SK, Yu VC (2007) Inhibition of ubiquitin-mediated degradation of MOAP-1 by apoptotic stimuli promotes Bax function in mitochondria. Proc Natl Acad Sci USA 104:10051–10056. https://doi.org/10.1073/pnas.0700007104 CrossRefPubMedPubMedCentral

Fussenegger M, Mazur X, Bailey JE (1998) pTRIDENT, a novel vector family for tricistronic gene expression in mammalian cells. Biotechnol Bioeng 57:1–10. https://doi.org/10.1002/(SICI)1097-0290(19980105)57:1%3c1:AID-BIT1%3e3.0.CO;2-M CrossRefPubMed

Ghazaleh HA, Chow RS, Choo SL et al (2010) 14–3-3 mediated regulation of the tumor suppressor protein, RASSF1A. Apoptosis 15:117–127. https://doi.org/10.1007/s10495-009-0451-6 CrossRefPubMed

Gil J, Yamamoto H, Zapata JM et al (1999) Impairment of the proapoptotic activity of BAX by missense mutations found in gastrointestinal cancers. Cancer Res 59:2034–2037 https://cancerres.aacrjournals.org/content/59/9/2034.long

Grill J, Lamfers MLM, van Beusechem VW et al (2002) The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 6:609–614. https://doi.org/10.1006/mthe.2002.0713 CrossRefPubMed

Hanson D, Murray PG, O’Sullivan J et al (2011) Exome sequencing identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth. Am J Hum Genet 89:148–153. https://doi.org/10.1016/j.ajhg.2011.05.028 CrossRefPubMedPubMedCentral

Hoffmann LA, Jarius S, Pellkofer HL et al (2008) Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 79:767–773. https://doi.org/10.1136/jnnp.2007.118588 CrossRefPubMed

Huang NJ, Zhang L, Tang W et al (2012) The Trim39 ubiquitin ligase inhibits APC/c cdh1-mediated degradation of the Bax activator MOAP-1. J Cell Biol 197:361–367. https://doi.org/10.1083/jcb.201111141 CrossRefPubMedPubMedCentral

Jones RG, Thompson CB (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23:537–548. https://doi.org/10.1101/gad.1756509 CrossRefPubMedPubMedCentral

Karagiannis GS, Pastoriza JM, Wang Y et al (2017) Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med 9:eaan0026. https://doi.org/10.1126/scitranslmed.aan0026 CrossRefPubMedPubMedCentral

Langhans SA (2018) Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol 9:6. https://doi.org/10.3389/fphar.2018.00006 CrossRefPubMedPubMedCentral

Law J, Salla M, Zare A et al (2015) Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein. J Biol Chem 290:24100–24118. https://doi.org/10.1074/jbc.M115.648345 CrossRefPubMedPubMedCentral

Law J, Yu VC, Baksh S (2012) Modulator of Apoptosis 1: a highly regulated RASSF1A-interacting BH3-like protein. Mol Biol Int 2012:536802. https://doi.org/10.1155/2012/536802 CrossRefPubMedPubMedCentral

Lee SS, Fu NY, Sukumaran SK et al (2009) TRIM39 is a MOAP-1-binding protein that stabilizes MOAP-1 through inhibition of its poly-ubiquitination process. Exp Cell Res 315:1313–1325. https://doi.org/10.1016/j.yexcr.2008.11.021 CrossRefPubMed

Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14:35–48. https://doi.org/10.1159/000086183 CrossRefPubMed

Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501:328–337. https://doi.org/10.1038/nature12624 CrossRefPubMedPubMedCentral

Moser S, Schlatter S, Fux C et al (2000) An update of pTRIDENT multicistronic expression vectors: pTRIDENTs containing novel streptogramin-responsive promoters. Biotechnol Prog 16:724–735. https://doi.org/10.1021/bp000077r CrossRefPubMed

Nagano S, Perentes JY, Jain RK, Boucher Y (2008) Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 68:3795–3802. https://doi.org/10.1158/0008-5472.CAN-07-6193 CrossRefPubMedPubMedCentral

Pan S-T, Li Z-L, He Z-X et al (2016) Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 43:723–737. https://doi.org/10.1111/1440-1681.12581 CrossRefPubMed

Pang SW, Lahiri C, Poh CL, Tan KO (2018) PNMA family: Protein interaction network and cell signalling pathways implicated in cancer and apoptosis. Cell Signal. https://doi.org/10.1016/j.cellsig.2018.01.022 CrossRefPubMed

Pfeifer GP, Dammann R (2005) Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochem 70:576–583. https://doi.org/10.1007/s10541-005-0151-y CrossRef

Ponnusamy S, He Y, Hwang DJ et al (2019) Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer. Clin Cancer Res 25:6764–6780. https://doi.org/10.1158/1078-0432.CCR-19-1458 CrossRefPubMed

Prasetyanti PR, Medema JP (2017) Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer 16:41. https://doi.org/10.1186/s12943-017-0600-4 CrossRefPubMedPubMedCentral

Raguz S, Yagüe E (2008) Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99:387–391. https://doi.org/10.1038/sj.bjc.6604510 CrossRefPubMedPubMedCentral

Rampino N, Yamamoto H, Ionov Y et al (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967–969. https://doi.org/10.1126/science.275.5302.967 CrossRefPubMed

Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta Rev Cancer 1796:114–128. https://doi.org/10.1016/j.bbcan.2009.03.004 CrossRef

Rosenfeld MR, Eichen JG, Wade DF et al (2001) Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50:339–348. https://doi.org/10.1002/ana.1094 CrossRefPubMed

Sahashi K, Sakai K, Mano K, Hirose G (2003) Anti-Ma2 antibody related paraneoplastic limbic/brain stem encephalitis associated with breast cancer expressing Ma1, Ma2, and Ma3 mRNAs. J Neurol Neurosurg Psychiatry 74(9):1332–1335. https://doi.org/10.1136/jnnp.74.9.1332 CrossRefPubMedPubMedCentral

Schuller M, Jenne D, Voltz R (2005) The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. J Neuroimmunol 169:172–176. https://doi.org/10.1016/j.jneuroim.2005.08.019 CrossRefPubMed

Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675. https://doi.org/10.1038/nmeth.2089 CrossRefPubMedPubMedCentral

Sun H, Wang G, Peng Y et al (2015) H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep 33:3045–3052. https://doi.org/10.3892/or.2015.3899 CrossRefPubMed

Takaji M, Komatsu Y, Watakabe A et al (2009) Paraneoplastic antigen-like 5 gene (PNMA5) is preferentially expressed in the association areas in a primate specific manner. Cereb Cortex 19:2865–2879. https://doi.org/10.1093/cercor/bhp062 CrossRefPubMedPubMedCentral

Tan KO, Fu NY, Sukumaran SK et al (2005) MAP-1 is a mitochondrial effector of Bax. Proc Natl Acad Sci USA 102:14623–14628. https://doi.org/10.1073/pnas.0503524102 CrossRefPubMedPubMedCentral

Tan KO, Tan KML, Chan SL et al (2001) MAP-1, a Novel proapoptotic protein containing a BH3-like motif that associates with Bax through Its Bcl-2 homology domains. J Biol Chem 276:2802–2807. https://doi.org/10.1074/jbc.M008955200 CrossRefPubMed

Tommasi S, Dammann R, Zhang Z et al (2005) Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65:92–98PubMed

Vergès B, Walter T, Cariou B (2014) ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170:R43–R55. https://doi.org/10.1530/EJE-13-0586 CrossRefPubMed

Voltz R, Gultekin SH, Rosenfeld MR et al (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340:1788–1795. https://doi.org/10.1056/NEJM199906103402303 CrossRefPubMed

Vos MD, Dallol A, Eckfeld K et al (2006) The RASSF1A tumor suppressor activates bax via MOAP-1. J Biol Chem 281:4557–4563. https://doi.org/10.1074/jbc.M512128200 CrossRefPubMed

Weiswald LB, Bellet D, Dangles-Marie V (2015) Spherical cancer models in tumor biology. Neoplasia (United States) 17:1–15. https://doi.org/10.1016/j.neo.2014.12.004 CrossRef

Wong HH, Lemoine NR, Wang Y (2010) Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2:78–106. https://doi.org/10.3390/v2010078 CrossRefPubMedPubMedCentral

Yamamoto H, Itoh F, Fukushima H, et al (1999) Frequent Bax frameshift mutations in gastric cancer with high but not low microsatellite instability. J Exp Clin Cancer Res 18:103–106 https://www.ncbi.nlm.nih.gov/pubmed/10374688

Zeyaullah M, Patro M, Ahmad I et al (2012) Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 18:771–781. https://doi.org/10.1007/s12253-012-9548-2 CrossRefPubMed

Title: Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1
Authors: Yong Hoi Lee
Siew Wai Pang
Esther Revai Lechtich
Khalid Shah
Samson Eugin Simon
Suriyan Ponnusamy
Ramesh Narayanan
Chit Laa Poh
Kuan Onn Tan
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keyword: Cytostatic Therapy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03231-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2020

A quick evaluation method of nosocomial infection risk for cancer hospitals during the COVID-19 pandemic

Active HPV infection and its influence on survival in head and neck squamous-cell cancer

Afatinib is active in osteosarcoma in osteosarcoma cell lines

Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation

Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase–negative cells

Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage